文献速递艾滋病与性传播感染

替莫瑞林对HIV感染者腹部肥胖者神经认知损害的影响

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity.
PubMed 文献 · J Infect Dis · 2025-01-01

这项为期6个月的2期随机开放标签临床试验,将73名病毒抑制且腹部肥胖的HIV感染者按3:2随机分配至替莫瑞林组(每日皮下注射2 mg)或标准治疗组。替莫瑞林组神经认知表现6个月时呈改善趋势(平均变化0.146;95%CI,-.002至.294;P=.060),但组间差异不显著(P=.673);替莫瑞林组腰围下降大于标准治疗组(中位差值-2.7 cm;P=.015)。作者认为短期减少腹部肥胖对神经认知损害无明显获益。

要点

  • 替莫瑞林组神经认知表现6个月呈改善趋势,但组间差异不显著(P=.673)。
  • 替莫瑞林组腰围下降大于标准治疗组(中位差值-2.7 cm;P=.015)。
  • IGF-1水平升高,但其变化与神经认知汇总回归变化评分或腰围不相关。

核心结论

  • 替莫瑞林降低了腰围,但两组的认知获益无显著差异。
  • 作者认识到把握度不足和无安慰剂组的局限,认为短期用替莫瑞林减少腹部肥胖对神经认知损害无明显获益。

研究设计与样本

  • 为期6个月的2期随机开放标签临床试验,比较替莫瑞林与标准治疗对病毒抑制且腹部肥胖(腰围升高)的HIV感染者神经认知损害的作用。
  • 73名参与者按3:2随机分配至替莫瑞林组(每日皮下注射2 mg)或标准治疗组。
  • 排除标准包括HIV以外导致神经认知损害的疾病、活动性物质使用障碍和恶性肿瘤。
  • 主要结局为6个月时神经认知表现的变化,次要结局包括腰围、情绪和日常功能。

主要发现

  • 替莫瑞林组6个月后神经认知表现呈改善趋势(平均变化0.146;95%CI,-.002至.294;P=.060),标准治疗组则无(0.103;95%CI,-.095至.301;P=.295),但组间差异不显著(P=.673)。
  • 替莫瑞林组腰围下降大于标准治疗组(中位差值-2.7 cm;P=.015)。
  • IGF-1水平升高,但其变化与神经认知汇总回归变化评分或腰围不相关。
  • 两组基线特征匹配良好。

关键数值与推荐

  • 替莫瑞林用法为每日皮下注射2 mg。
  • 随机比例为替莫瑞林组比标准治疗组为3:2。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 把握度不足。
  • 无安慰剂组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity (AO) is linked to neurocognitive impairment (NCI), potentially due to visceral adiposity, inflammation, and reduced insulin-like growth factor 1 (IGF-1). Tesamorelin, a growth hormone-releasing hormone, reduces AO and increases IGF-1, suggesting that it might mitigate NCI in people with HIV and viral suppression. METHODS: This 6-month phase 2 randomized open-label clinical trial compared tesamorelin vs standard of care (SOC) for NCI in people with HIV who were virally suppressed and abdominally obese (elevated waist circumference [WC]). Exclusions included conditions other than HIV causing NCI, active substance use disorder, and malignancy. RESULTS: Seventy-three participants were randomized 3:2 to tesamorelin or SOC (2 mg subcutaneously daily). The primary outcome was the change in neurocognitive performance at 6 months, with secondary outcomes including WC, mood, and daily functioning. The groups were well matched at baseline. The tesamorelin group showed a trend toward improved neurocognitive performance after 6 months (mean change, 0.146; 95% CI, -.002 to .294; P = .060) while the SOC group did not (0.103; 95% CI, -.095 to .301; P = .295), but the between-group difference was not significant (P = .673). IGF-1 levels increased, but changes did not correlate with summary regression change score or WC. The tesamorelin group had a greater reduction in WC than the SOC group (median difference, -2.7 cm; P = .015). CONCLUSIONS: While tesamorelin reduced WC, the cognitive benefits did not significantly differ between groups. Recognizing the limitations of insufficient power and no placebo arm, this study suggests no clear benefit of short-term AO reduction with tesamorelin on NCI.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ellis RJ, Vaida F, Hu K, et al. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity. J Infect Dis. 2025. PMID: 39813152. doi:10.1093/infdis/jiaf012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。